Cardiovascular morbidity and mortality remain high in ESRD patients. Lipid abnormalities in CAPD may be more important than in hemodialysis. Vessel calcification may have a role in atherosclerotic heart disease, but this is only an inference from several clinical observations, and it remains to be defined more clearly as a risk factor. Left ventricular hypertrophy is frequent in this patient population, and is associated with specific clinical patterns and an in creased risk of death. Erythropoietin treatment of anemia and tight blood pressure controls have proved to help in reversing severe left ventricular hypertrophy. Finally, we describe a syndrome of the hypertrophic, high cardiac output hemodialysis heart, which is characterized by a high cardiac output in hemodialysis patients. It is associated with left ventricular hypertrophy and eventually right ventricular hypertrophy with tricuspid insufficiency. This may require fistula revision and even a switch to peritoneal dialysis.
U. S. Renal Data System.USRDS 1993 Annual Data Report.Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1993.
2.
FassbinderW., BrunnerF.P., BryngerH.Combined report on regular dialysis and transplantation in Europe xx, 1989.Nehprol Dial Transplant1991; 6(Suppl 1): 5–35.
3.
U. S. Renal Data System.USRDS 1991 Annual Data Report. Survival probabilities and causes of death.Am J Kidney Dis1991; 18(Suppl 2): 49–60.
4.
MaillouxL.U., BelluciA.G., WilkesE.M.Mortality in dialysis patients: analysis of the causes of death.Am J Kidney Dis1991; 18: 326–35.
5.
PortF.K.Mortality and causes of death in patients with end-stage renal failure.Am J Kidney Dis1990; 15: 215–17.
6.
BloembergenW.E., PortF.K., MaugerE.A., WolfeR.A.Causes of death in dialysis patients: racial and gender differences.J Am Soc Nephrol1994; 5: 1231–42.
7.
Personal Communication. P. Parfrey. Data from a paper submitted to Am J Nephrol.FoleyR.N.Hypocalcemia, morbidity and mortality in end-stage renal disease.
8.
HutchisonA.J., WhitehouseR.W., FreemontA.J., AdamsJ.F., MawerD.B., GokalR.Histological, radiological and biochemical features of the adynamic bone lesion in CAPD patients.Am J Nephrol1994; 14: 19–29.
9.
SnidermanA.D., CianfloneK., KwiterovichP.O.Jr., HutchinsonT., BarréP., PrichardS.Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis.Atherosclerosis1987; 65(3): 257–64.
10.
ZilversmitD.B., NordestguardB.G.Comparison of arterial intimal clearances of LDL from diabetic and nondiabetic cholesterol-fed rabbits.Arteriosclerosis1989; 9: 176–83.
11.
DeGraafJ., HaklemmasH.L.M., HectorsM.P.C., DemackerP.N.M., HedricksJ.C.M., StalenhalfA.F.H.Enhances susceptibility toin vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.Arteriosclerosis1991; 11: 298–306.
12.
Hurt-CamejoE., CamejoG., RosengrenE., LopezF., WiklandO., BondersG.Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages.J LipidRes1990; 31: 1387–98.
13.
WeisserB., LocherR., DeGraafJ., MoserR., SachinidesA., VetterW.Low density lipoprotein subfractions increase thromboxane formation in endothelial cells.Biochem Biophys Res Commun1993; 192: 1245–50.
14.
CianfloneK., DahanS., MongeJ.C., SnidermanA.D.Pathogenesis of carbohydrate induced hypertrigly ceridemia using HepG2 cells as a model system.Arterioscler Thromb1992; 12(3): 271–7.
15.
CianfloneK., VuH., ZhangZ., SnidermanA.D.Effects of albumin on lipid synthesis, apoB100 secretion, and LDL catabolism in HepG2 cells.Atherosclerosis1994; 107: 125–35.
16.
ZhangZ., SnidermanA.D., KalantD.The role of amino acids in apoB100 synthesis and catabolism in human HepG2 cells.J Biol Chem1993; 268(36): 26920–6.
17.
Scandinavian Simvastatin Survival Group.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease.Lancet1994; 344: 1383–9.
18.
FurbergC.D., AdamsHPJr., Applegate WB, . Effect of lovastatin on early carotid atherosclerosis and car diovascular events.Circulation1994; 90(4): 1679–87.
19.
TreasureC.B., KleinL.J., WeintraubW.S.Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.N Engl J Med1995; 332: 481–7.
20.
AndersonT.J., MeredithI.T., YeungA.C., FreiB., SelwynA.P., GanzP.The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.N Engl J Med1995; 332: 488–93.
21.
ParfreyP.S., HarnettJ.D., GriffithsS.M.The clinical course of left ventricular hypertrophy in dialysis patients.Nephron1990; 55: 114–20.
22.
HuttingJ., KramerW., SchutterleG., WizemannV.Analysis of left ventricular changes associated with chronic hemodialysis: a non-invasive follow-up study.Nephron1988; 49: 284–90.
HarnettJ.D., KentG.M., BarréP.E., TaylorR., ParfreyP.S.Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients.J Am Soc Nephrol1994; 4: 1486–90.
25.
FoleyR.N., ParfreyP.S., HarnettJ.D.Clinical and echocardiographic disease in patients starting endstage renal disease therapy.Kidney Int1995; 47: 186–92.
ParfreyP.S., GriffithsS.M., HamettJ.D.Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease and ischemic heart disease in dialysis patients.Am J Nephrol1990; 10: 213–21.
28.
HarnettJ.D., FoleyR.N., KentG.M., BarréP.E., MurrayD., ParfreyP.S.Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors.Kidney Int1995; 47: 884–90.
29.
LevyD., GarrisonR.J., SavageD.D., KannelW.R., CastelliW.P.Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.N Engl J Med1990; 322: 1561–6.
30.
SilberbergJ.S., BarréP., PrichardS., SnidermanA.D.; Left ventricular hypertrophy: an independent determinant of survival in end stage renal disease.Kidney Int1989; 36: 286–90.
31.
SilberbergJ., RacineN., BarréP., SnidermanA.D.Regression of left ventricular hypertrophy in dialysis following correction of anemia with recombinant human erythropoietin.Can J Cardiol1990; 6: 1–4.
32.
ZehnderC., ZuberM., SulzerM.Influence of longterm amelioration of anemia and blood pressure on left ventricular hypertrophy in hemodialysis patients.Nephron1992; 64: 202–6.
33.
CanellaG., PaolettiE., DelfineoR., PelosoG., MolinariS., Battista TraversonG.Regression of left ventricular hypertrophy in hypertensive dialyzed patients on longterm antihypertensive therapy.Kidney Int1993; 44: 881–6.
